An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
Repare Therapeutics and Debiopharm have dosed the first patient in the Phase 1/1b MYTHIC trial, evaluating the combination of PKMYT1 and WEE1 inhibition. This collaboration aims to assess safety, pharmacokinetics, and preliminary clinical activity of lunresertib and Debio 0123, showing promise for cancer patients.
Repare Therapeutics e Debiopharm hanno somministrato il trattamento al primo paziente nel trial di Fase 1/1b MYTHIC, valutando la combinazione degli inibitori PKMYT1 e WEE1. Questa collaborazione mira a valutare la sicurezza, la farmacocinetica e l'attività clinica preliminare di lunresertib e Debio 0123 nei pazienti oncologici. I composti mostrano un potenziale per una terapia trasformativa con alta sinergia, rapidi regressi tumorali e tollerabilità clinica.
Repare Therapeutics y Debiopharm han administrado dosis al primer paciente en el ensayo de Fase 1/1b MYTHIC, evaluando la combinación de los inhibidores PKMYT1 y WEE1. Esta colaboración tiene como objetivo evaluar la seguridad, la farmacocinética y la actividad clínica preliminar de lunresertib y Debio 0123 en pacientes con cáncer. Los compuestos tienen potencial para una terapia transformadora con alta sinergia, regresiones tumorales rápidas y tolerabilidad clínica.
Repare Therapeutics와 Debiopharm는 1/1b 단계 MYTHIC 시험에서 첫 환자에게 PKMYT1 및 WEE1 억제제의 조합을 투여했습니다. 이 협력은 암 환자에서 lunresertib 및 Debio 0123의 안전성, 약동학 및 초기 임상 활동을 평가하는 것을 목표로 합니다. 이 화합물들은 높은 시너지, 빠른 종양 감소 및 임상적 내약성으로 변혁적인 치료 가능성을 보여줍니다.
Repare Therapeutics et Debiopharm ont administré le traitement au premier patient dans l'essai de Phase 1/1b MYTHIC, évaluant la combinaison des inhibiteurs PKMYT1 et WEE1. Cette collaboration vise à évaluer la sécurité, la pharmacocinétique et l'activité clinique préliminaire de lunresertib et Debio 0123 chez les patients atteints de cancer. Les composés montrent un potentiel pour une thérapie transformative avec une grande synergie, des régressions tumorales rapides et une tolérabilité clinique.
Repare Therapeutics und Debiopharm haben den ersten Patienten in der Phase-1/1b MYTHIC-Studie behandelt, in der die Kombination der Inhibitoren PKMYT1 und WEE1 untersucht wird. Diese Zusammenarbeit zielt darauf ab, die Sicherheit, Pharmakokinetik und vorläufige klinische Aktivität von Lunresertib und Debio 0123 bei Krebspatienten zu beurteilen. Die Verbindungen zeigen Potenzial für eine transformative Therapie mit hoher Synergie, schnellen Tumorregressionen und klinischer Verträglichkeit.
Positive
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution of clinical development and further characterization of precision medicine therapies.
Negative
None.
MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating lunresertib in combination with Debio 0123. In this trial, Debiopharm and Repare seek to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of this PKMYT1 and WEE1 inhibitor combination.
In early January, Repare and Debiopharm announced a collaboration to evaluate the clinical combination of lunresertib, a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, and Debio 0123, an oral, brain-penetrant, highly selective WEE1 kinase inhibitor. This collaboration is based on preclinical in vivo data and other data showing rapid, remarkable tumor regressions and high predicted clinical tolerability and represents the first clinical-stage approach to inhibiting both PKMYT1 and WEE1.
“We are excited to have treated our first patient with lunresertib and Debio 0123,” said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. “Each of these compounds is well understood and clinically characterized. This combination provides us a unique opportunity to optimize dosing between two selective compounds and overcome limitations inherent to dual-inhibitor approaches. We expect this clinical collaboration will allow us to optimize the excellent synergy we saw preclinically to maximize patient benefit and tolerability.”
"Lunresertib and Debio 0123 have the potential to be a transformative combination therapy for cancer patients with high unmet medical need,” said Angela Zubel, Chief Development Officer of Debiopharm. “Treating the first patient in this new Module of the MYTHIC clinical trial is an important milestone for our collaboration, as it allows us to execute clinical development swiftly. We look forward to working closely with Repare to further characterize these innovative precision medicine therapies.”
About Lunresertib
Lunresertib (RP-6306) is a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, a cancer target Repare discovered and identified as synthetic lethal with CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors. Lunresertib is currently the sole PKMYT1 inhibitor known to be in clinical trials and is being evaluated alone and in combinations across several studies in the US, UK/EU4, and Canada. Repare has presented positive initial Phase 1 data from its ongoing Phase 1/1b MYTHIC trial (NCT04855656) demonstrating proof of concept for lunresertib alone and in combination. In addition to being well tolerated and having a compelling safety profile, Repare presented anti-tumor activity for lunresertib in combination with camonsertib, an ATR inhibitor developed by Repare, expanded clinical studies for which are ongoing.
About Debio 0123
Debio 0123 is an oral, brain-penetrant, highly selective WEE1 kinase inhibitor. WEE1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage and replication stress, allowing cells to repair their DNA before resuming their cell cycle. WEE1 inhibition, particularly in combination with DNA damaging agents, induces an accumulation of DNA damage and pushes the cells through cell cycle without DNA repair, promoting mitotic catastrophe and induction of apoptosis in cancer cells. Debio 0123 is currently being investigated in clinical trials in patients with solid tumors as a monotherapy and in combination. Debio 0123 is being developed to address high unmet needs of patients living with the burden of difficult-to-treat cancers.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor program; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
Debiopharm's Commitment to Patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s clinical collaboration with Debiopharm including the benefits and results that may be achieved through the collaboration; the potential therapeutic benefits of lunresertib in combination with Debio 0123; and the anticipated timing, patient enrollment, outcomes or associated costs of the Phase 1/1b clinical trial of lunresertib in combination with Debio 0123, including timing of preliminary data from Module 4 of the MYTHIC trial. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the impacts of macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine, the Hamas-Israel conflict, heightened inflation and uncertain credit and financial markets on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risk that Repare may not realize the potential benefits of this collaboration with Debiopharm; the discovery, development and potential commercialization of potential product candidates using Repare’s SNIPRx® platform technology , including the development of lunresertib under the clinical study and collaboration agreement; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers ("AMF") on February 28, 2024. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on Twitter at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Investor Relations & Media:
Robin Garner
Vice President and Head of Investor Relations
Repare Therapeutics Inc.
investor@reparerx.com
Source: Repare Therapeutics Inc.
FAQ
<p>What is the Phase 1/1b MYTHIC trial evaluating?</p>
The Phase 1/1b MYTHIC trial is evaluating the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer patients.
<p>What are lunresertib and Debio 0123?</p>
Lunresertib is a first-in-class inhibitor of PKMYT1, and Debio 0123 is a highly selective WEE1 kinase inhibitor, both showing promise in tumor regressions.
<p>Who announced the collaboration to evaluate lunresertib and Debio 0123?</p>
Repare Therapeutics and Debiopharm announced the collaboration to evaluate the clinical combination of lunresertib and Debio 0123.
repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.
